What is IMV Inc. (IMV.TO)?

IMV Inc. (IMV.TO) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

IMV Inc. (IMV.TO)

Stock analysis · TSX · Healthcare · Biotechnology

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

1.52

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

IMV Inc. (IMV.TO) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 16, 2023

EPS $-0.99 vs est. $-1.20

Beat by $0.21

Proprietary Signals

Signal snapshot temporarily unavailable.

About IMV Inc.

IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.